Stock listing
NASDAQ:CVKD Cadrenal Therapeutics, Inc. Stock
Home listing (NASDAQ) of Cadrenal Therapeutics, Inc.
Follow Cadrenal Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:CVKD
$1.70 USD -0.02 (-1.2%)
Close on Nov 20, 2026
- Day range
- $1.52 – $1.85 USDNov 20, 2026
- Volume
- 206,569 sharesNov 20, 2026
- Market cap
- $7.01M USDAt the close on Nov 20, 2026 · price × 4.12M shares outstanding
- 52-week range
- $0.816 – $12.50 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $770,236 USDMedian day 88,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CVKD · Home | $1.70 USD | -0.02 (-1.2%) | 206,569 | $1.69 | $1.85 | $1.523 | $1.72 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CVKD · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.70 | -0.02 | -1.2% | $1.69 | $1.85 | $1.523 | 206,569 | |
| $1.72 | -0.16 | -8.5% | $1.84 | $1.84 | $1.55 | 259,403 | |
| $1.88 | +0.48 | +34.3% | $1.34 | $1.92 | $1.34 | 382,569 | |
| $1.40 | -0.11 | -7.3% | $1.49 | $1.58 | $1.38 | 74,959 | |
| $1.51 | 0.00 | 0.0% | $1.49 | $1.56 | $1.43 | 42,092 | |
| $1.51 | +0.06 | +4.1% | $1.41 | $1.56 | $1.36 | 184,487 | |
| $1.45 | +0.01 | +0.7% | $1.47 | $1.48 | $1.30 | 88,800 | |
| $1.44 | +0.07 | +5.1% | $1.36 | $1.49 | $1.278 | 192,200 | |
| $1.37 | +0.39 | +39.8% | $0.98 | $1.38 | $0.959 | 374,500 | |
| $0.98 | -0.02 | -2.0% | $1.02 | $1.09 | $0.98 | 28,400 | |
| $1.00 | -0.06 | -5.7% | $1.06 | $1.07 | $0.99 | 93,700 | |
| $1.06 | -0.07 | -6.2% | $1.10 | $1.15 | $1.05 | 43,200 | |
| $1.13 | +0.09 | +8.7% | $1.05 | $1.14 | $1.05 | 55,300 | |
| $1.04 | +0.055 | +5.6% | $0.923 | $1.23 | $0.923 | 284,800 | |
| $0.985 | +0.042 | +4.5% | $0.94 | $1.00 | $0.94 | 80,700 | |
| $0.943 | -0.005 | -0.5% | $0.94 | $1.00 | $0.94 | 44,000 | |
| $0.948 | +0.006 | +0.6% | $0.91 | $0.981 | $0.91 | 37,500 | |
| $0.942 | +0.032 | +3.5% | $0.90 | $0.99 | $0.86 | 60,400 | |
| $0.91 | -0.05 | -5.2% | $0.95 | $0.96 | $0.91 | 52,200 | |
| $0.96 | -0.01 | -1.0% | $0.965 | $1.00 | $0.93 | 38,200 | |
| $0.97 | -0.05 | -4.9% | $1.03 | $1.07 | $0.96 | 19,800 | |
| $1.02 | -0.02 | -1.9% | $1.02 | $1.03 | $1.00 | 28,200 | |
| $1.04 | -0.02 | -1.9% | $1.04 | $1.10 | $1.00 | 48,700 | |
| $1.06 | -0.03 | -2.8% | $1.06 | $1.10 | $0.998 | 152,200 | |
| $1.09 | +0.12 | +12.4% | $0.96 | $1.12 | $0.96 | 173,200 | |
| $0.97 | -0.05 | -4.9% | $0.99 | $1.03 | $0.965 | 104,200 | |
| $1.02 | +0.023 | +2.3% | $0.93 | $1.10 | $0.92 | 344,300 | |
| $0.997 | +0.125 | +14.3% | $0.889 | $1.06 | $0.874 | 376,400 | |
| $0.872 | -0.038 | -4.2% | $0.918 | $0.918 | $0.816 | 111,400 | |
| $0.91 | -0.02 | -2.2% | $0.974 | $0.974 | $0.90 | 82,400 | |
| $0.93 | -0.042 | -4.3% | $0.994 | $0.994 | $0.87 | 311,200 | |
| $0.972 | -0.018 | -1.8% | $1.01 | $1.07 | $0.917 | 1,781,700 | |
| $0.99 | +0.044 | +4.7% | $0.943 | $1.05 | $0.90 | 98,000 | |
| $0.946 | +0.006 | +0.6% | $0.97 | $1.00 | $0.935 | 63,000 | |
| $0.94 | -0.03 | -3.1% | $0.98 | $1.005 | $0.85 | 149,600 | |
| $0.97 | -0.11 | -10.2% | $1.09 | $1.09 | $0.97 | 109,200 | |
| $1.08 | -0.01 | -0.9% | $1.10 | $1.10 | $1.05 | 21,700 | |
| $1.09 | -0.03 | -2.7% | $1.10 | $1.13 | $1.08 | 38,200 | |
| $1.12 | -0.03 | -2.6% | $1.16 | $1.16 | $1.07 | 75,600 | |
| $1.15 | -0.05 | -4.2% | $1.25 | $1.25 | $1.13 | 224,700 | |
| $1.20 | -0.12 | -9.1% | $1.31 | $1.355 | $1.19 | 119,000 | |
| $1.32 | +0.20 | +17.9% | $1.12 | $1.348 | $1.06 | 269,000 | |
| $1.12 | +0.03 | +2.8% | $1.11 | $1.139 | $1.06 | 73,500 | |
| $1.09 | +0.02 | +1.9% | $1.07 | $1.11 | $1.06 | 66,800 | |
| $1.07 | -0.05 | -4.5% | $1.12 | $1.16 | $1.07 | 113,600 | |
| $1.12 | +0.04 | +3.7% | $1.10 | $1.14 | $1.08 | 44,900 | |
| $1.08 | +0.03 | +2.9% | $1.05 | $1.10 | $1.01 | 55,600 | |
| $1.05 | -0.01 | -0.9% | $1.06 | $1.12 | $1.04 | 56,400 | |
| $1.06 | -0.03 | -2.8% | $1.07 | $1.10 | $1.054 | 47,600 | |
| $1.09 | -0.09 | -7.6% | $1.17 | $1.189 | $1.00 | 228,600 | |
| $1.18 | -0.01 | -0.8% | $1.17 | $1.20 | $1.14 | 119,800 | |
| $1.19 | -0.01 | -0.8% | $1.22 | $1.23 | $1.14 | 114,600 | |
| $1.20 | -0.02 | -1.6% | $1.20 | $1.26 | $1.16 | 161,800 | |
| $1.22 | -0.06 | -4.7% | $1.26 | $1.295 | $1.20 | 177,400 | |
| $1.28 | -0.05 | -3.8% | $1.34 | $1.41 | $1.27 | 168,600 | |
| $1.33 | -0.18 | -11.9% | $1.40 | $1.53 | $1.28 | 388,300 | |
| $1.51 | -0.24 | -13.7% | $1.49 | $1.58 | $1.42 | 783,800 | |
| $1.75 | +0.21 | +13.6% | $1.64 | $2.29 | $1.46 | 21,599,200 | |
| $1.54 | -0.025 | -1.6% | $1.56 | $1.60 | $1.50 | 31,100 | |
| $1.565 | +0.015 | +1.0% | $1.52 | $1.622 | $1.52 | 48,200 | |
| $1.55 | +0.02 | +1.3% | $1.56 | $1.643 | $1.49 | 24,700 | |
| $1.53 | -0.04 | -2.5% | $1.56 | $1.61 | $1.50 | 39,200 | |
| $1.57 | -0.04 | -2.5% | $1.69 | $1.69 | $1.54 | 36,200 | |
| $1.61 | +0.02 | +1.3% | $1.62 | $1.62 | $1.541 | 36,200 | |
| $1.59 | -0.05 | -3.0% | $1.65 | $1.725 | $1.58 | 60,000 |
Splits
1 split · NASDAQ:CVKD · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-15 | Consolidation |
- Ticker
- NASDAQ:CVKD
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 7, 2026
Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 21 slides
Latest news
Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics
Oct 7, 2026
Closed $0.972 (-1.8%) on Oct 7, 2026
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
Sep 21, 2026
Closed $1.12 (+2.8%) on Sep 22, 2026
Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
Sep 3, 2026
Closed $1.28 (-3.8%) on Sep 3, 2026
Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
Aug 31, 2026
Closed $1.75 (+13.6%) on Aug 31, 2026
Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
Aug 13, 2026
Closed $1.87 (+0.5%) on Aug 14, 2026
Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
Jul 21, 2026
Closed $2.17 (+3.8%) on Jul 21, 2026
Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress
Jul 13, 2026
Closed $2.42 (-16.3%) on Jul 13, 2026
Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Jun 30, 2026
Closed $3.17 (-5.1%) on Jul 1, 2026
Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress
Jun 24, 2026
Closed $2.98 (-2.6%) on Jun 24, 2026
Cadrenal Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 25 in the last 12 months · 92 in all · newest Oct 7, 2026 · oldest 2023
- Decks
- 14 decks · latest September 2026
Where Cadrenal Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CVKD · Home listing · This page | NASDAQ | United States | USD |
| BOATS:CVKD | BOATS | United States | USD |
Valuation
Price/book 2.4× against a median of 2.8×: 5th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $3.95M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.60
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Cadrenal Therapeutics, Inc. · NASDAQ:CVKD | US$7.01M | US$3.95M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.60 |
| Ascelia Pharma AB · OMXSTO:ACE | US$7.30M | US$3.63M | n/a | n/a | n/a | 0.8× | n/a | 0.0× | n/a |
| AEON Biopharma, Inc. · AMEX:AEON | US$7.27M | −US$4.15M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | 1.04 |
| Pila Pharma AB · OMXSTO:PILA | US$7.01M | US$6.70M | n/a | n/a | n/a | 4.5× | n/a | 0.0× | n/a |
| Ensysce Biosciences, Inc. · NASDAQ:ENSC | US$7.00M | −US$22.51M | n/a | −3.6× | n/a | 0.3× | n/a | 0.0× | 1.28 |
| Arctic Bioscience AS · OSL:ABS | US$7.00M | US$11.38M | n/a | 2.8× | n/a | 0.4× | −102.3% | 0.3× | n/a |
| Alaunos Therapeutics, Inc. · NASDAQ:TCRT | US$6.99M | US$6.37M | n/a | 2,124× | n/a | 7.2× | n/a | 0.0× | 0.90 |
| Curanex Pharmaceuticals Inc · NASDAQ:CURX | US$6.92M | US$5.88M | n/a | n/a | n/a | 2.7× | n/a | 0.2× | 0.84 |
| Cambium Bio Ltd · ASX:CMB | US$6.82M | US$6.18M | n/a | 14.6× | n/a | 4.3× | −638.4% | 0.1× | n/a |
| MetaVia Inc. · NASDAQ:MTVA | US$6.81M | −US$1.97M | n/a | n/a | n/a | 2.8× | n/a | 0.0× | 1.22 |
| Aligos Therapeutics, Inc. · NASDAQ:ALGS | US$6.64M | −US$12.55M | n/a | −2.1× | n/a | 0.6× | n/a | 1.1× | 1.63 |
| Median of the others | US$6.99M | US$4.75M | 2.8× | 2.8× | −370.4% | 0.0× | 1.13 |
Forecasts
2 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 14.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.92 · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Quang Pham | Chairman & Chief Executive Officer |
| John P. Sharp | Interim Chief Financial Officer |
| Jeff Cole | Chief Operating Officer |
Board
| Director | Role |
|---|---|
| Quang Pham | Chairman & Chief Executive Officer |
| Glynn Wilson | Board Member |
| John R. Murphy | Board Member |
| Lee Golden | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · After close | +34.3% |
| Q2 2026 | Aug 13, 2026 · After close | +0.5% |
| Q1 2026 | May 7, 2026 · Before open | −2.4% |
| Q3 2025 | Nov 10, 2025 · Before open | −3.2% |
| Q2 2025 | Aug 11, 2025 · Before open | −1.9% |
| Q1 2025 | May 8, 2025 · After close | −6.8% |
| Q4 2024 | Mar 13, 2025 | +8.0% |
| Q3 2024 | Nov 7, 2024 · After close | +8.9% |
| Q2 2024 | Aug 7, 2024 · After close | +4.7% |
| Q1 2024 | May 9, 2024 · Before open | −1.1% |
All 15 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 11, 2024 · Before open | −2.8% |
| Q3 2023 | Nov 11, 2023 · After close | −2.9% |
| Q2 2023 | Aug 30, 2023 | +8.4% |
| Q4 2022 | Mar 30, 2023 | +9.3% |
| Q2 2022 | Sep 22, 2022 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 21 slides | September 2026 |
| Investor Presentation (May 2026) | Investor deck | 18 slides | May 2026 |
| Investor Presentation (December 2025) | Investor deck | 23 slides | Dec 11, 2025 |
| Investor Presentation (September 2025) | Investor deck | 26 slides | Sep 15, 2025 |
| Investor Presentation (September 2024) | Investor deck | 34 slides | Sep 25, 2024 |
| Investor Presentation (September 2024) | Investor deck | 34 slides | September 2024 |
| Investor Presentation (August 2024) | Investor deck | 27 slides | August 2024 |
| Investor Presentation (July 2024) | Investor deck | 31 slides | Jul 30, 2024 |
| Investor Presentation (May 2024) | Investor deck | 29 slides | May 2024 |
| Investor Presentation (March 2024) | Investor deck | 37 slides | Mar 11, 2024 |
All 14 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (December 2023) | Investor deck | 37 slides | December 2023 |
| Investor Presentation (August 2023) | Investor deck | 36 slides | August 2023 |
| Investor Presentation (May 2023) | Investor deck | 32 slides | May 2023 |
| Investor Presentation (March 2023) | Investor deck | 32 slides | March 2023 |
IPO
Priced at US$5.00 a share on Jan 19, 2023.
- Price
- US$5.00 a share
- Shares offered
- 3,104,783 shares of common stock · 1,400,000 from the company and 1,704,783 from selling shareholders
- Offering size
- US$7 million
- Underwriters' option
- Up to 210,000 more shares
- Listing
- CVKD on the Nasdaq Capital Market
- Underwriters
- Boustead Securities, LLC, Sutter Securities, Inc., Revere Securities LLC · In the order on the cover
- Shares delivered
- On or about Jan 24, 2023
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jul 15, 2022 |
| Filed publicly | Sep 22, 2022 |
| Amended 6 times | Newest Jan 17, 2023 |
| Shares registered with an exchange | Jan 17, 2023 |
| Declared effective by the SEC | Jan 19, 2023 |
| Final prospectus, with the price | Jan 23, 2023 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jan 23, 2023 |
| 424B4 · Prospectus | Jan 23, 2023 |
| CERT · Exchange's certificate of listing | Jan 20, 2023 |
| EFFECT · Notice that a registration is effective | Jan 19, 2023 |
| 8-A12B · Registration of shares for listing on an exchange | Jan 17, 2023 |
| CORRESP · Letter to the SEC | Jan 17, 2023 |
| CORRESP · Letter to the SEC | Jan 17, 2023 |
| S-1/A · Registration statement, amended | Jan 17, 2023 |
| S-1/A · Registration statement, amended | Dec 28, 2022 |
| CORRESP · Letter to the SEC | Dec 8, 2022 |
All 26 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Dec 8, 2022 |
| UPLOAD · Letter from the SEC | Dec 8, 2022 |
| S-1/A · Registration statement, amended | Dec 6, 2022 |
| S-1/A · Registration statement, amended | Oct 17, 2022 |
| CORRESP · Letter to the SEC | Oct 17, 2022 |
| UPLOAD · Letter from the SEC | Oct 13, 2022 |
| S-1/A · Registration statement, amended | Oct 11, 2022 |
| CORRESP · Letter to the SEC | Sep 22, 2022 |
| S-1 · Registration statement | Sep 22, 2022 |
| DRSLTR · Letter to the SEC with a draft | Sep 2, 2022 |
| DRS/A · Draft registration statement, amended | Sep 2, 2022 |
| UPLOAD · Letter from the SEC | Aug 30, 2022 |
| DRSLTR · Letter to the SEC with a draft | Aug 23, 2022 |
| DRS/A · Draft registration statement, amended | Aug 23, 2022 |
| UPLOAD · Letter from the SEC | Aug 11, 2022 |
| DRS · Draft registration statement | Jul 15, 2022 |
Open IPO · From the cover of the final prospectus (424B4) filed Jan 23, 2023
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2008 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | ||
| Cost of revenue | 1.88K | 220.1K | 1.27K | 220.1K | |
| Gross profit | -1.88K | -1.98K | -1.27K | ||
| Research and development | 4.10M | 4.21M | 4.08M | 392.9K | 200.0K |
| Selling, general and administrative | 9.35M | 6.75M | 3.55M | ||
| Operating income | -13.5M | -11.0M | -7.63M | -2.70M | |
| Depreciation and amortization | 6.87K | 1.88K | 1.98K | 1.27K | |
| EBITDA | -13.5M | -11.0M | -7.63M | -2.70M | |
| Interest expense | 0 | 3.53K | 107.1K | ||
| Income before tax | -13.2M | -10.7M | -8.36M | -6.71M | |
| Income tax | -165.9K | 4 | |||
| Net income | -13.2M | -10.7M | -8.36M | -6.71M | |
| Earnings per share, basic | -6.64 | -8.73 | -9.29 | -8.66 | |
| Earnings per share, diluted | -6.64 | -8.73 | -9.29 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2008 |
|---|---|---|---|---|---|
| Cash and equivalents | 4.01M | 10.0M | 8.40M | 32.6K | |
| Receivables | 5.10K | 38.2K | 37.2K | ||
| Current assets | 4.32M | 10.1M | 8.49M | 727.6K | |
| Property, plant and equipment | 5.17K | 6.94K | 2.29K | 44.6K | |
| Total assets | 4.33M | 10.1M | 8.52M | 778.2K | |
| Accounts payable | 650.7K | 1.50M | 167.3K | 404.9K | |
| Current liabilities | 1.59M | 2.68M | 826.9K | 1.33M | |
| Long-term debt | 553.3K | ||||
| Total debt | 21.4K | 640.7K | |||
| Total liabilities | 1.59M | 2.68M | 826.9K | 6.33M | |
| Shareholders' equity | 2.74M | 7.44M | 7.69M | -5.55M | |
| Shares outstanding | 2.34M | 1.78M | 868.2K | 775.6K | 11.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | -12.6M | -7.36M | -3.53M | -1.31M |
| Capital spending | -5.10K | -6.54K | -3.25K | -2.49K |
| Free cash flow | -12.6M | -7.36M | -3.53M | -1.32M |
| Cash from investing | -5.10K | -6.54K | -3.25K | -2.49K |
| Cash from financing | 6.60M | 8.98M | 11.9M | 1.35M |
| Share buybacks | -291.9K | 0 | ||
| Change in cash | -6.01M | 1.62M | 8.37M | 32.6K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 17, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Oct 8, 2026 | Offer document | SEC |
| 8-K · Current report | Oct 7, 2026 | Current report | SEC |
| 8-K · Current report | Sep 29, 2026 | Management or board change | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| S-8 · Registration statement for employee plans | Sep 3, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 31, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 7, 2026 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Aug 3, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Aug 3, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Aug 3, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jul 23, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jul 21, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jul 21, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Jul 20, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 17, 2026 | Management or board change | SEC |
| D | Jul 15, 2026 | Other filings | SEC |
| S-3 · Registration statement | Jul 13, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 10, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 1, 2026 | Material contract | SEC |
| 8-K · Current report | Jun 29, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 3, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 11, 2026 | Other filings | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | Apr 30, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Apr 30, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Apr 29, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 27, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 27, 2026 | Other filings | SEC |
| S-3 · Registration statement | Apr 20, 2026 | Offer document | SEC |
| D | Apr 6, 2026 | Other filings | SEC |
| 8-K · Current report | Apr 1, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Apr 1, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 31, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2026 | Results | SEC |
| 8-K · Current report | Mar 12, 2026 | Current report | SEC |
| 8-K · Current report | Feb 24, 2026 | Current report | SEC |
| 424B3 · Prospectus | Jan 2, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 2, 2026 | Other filings | SEC |
| D | Dec 31, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 31, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Dec 31, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 30, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 29, 2025 | Other filings | SEC |
| S-1 · Registration statement | Dec 23, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 23, 2025 | Current report | SEC |
| 424B5 · Prospectus | Dec 23, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 16, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Dec 16, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Dec 16, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 11, 2025 | Material contract | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 1, 2025 | Management or board change | SEC |
| 8-K · Current report | Nov 18, 2025 | Current report | SEC |
| 424B5 · Prospectus | Nov 18, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 28, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 27, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 27, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 24, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 14, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 14, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 14, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 9, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 9, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 6, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 1, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 1, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 29, 2025 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | Sep 29, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 25, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 25, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 24, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 24, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Sep 15, 2025 | Material contract | SEC |
| 4 · Change in ownership | Aug 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 28, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 28, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 27, 2025 | Other filings | SEC |
| 144/A · Notice of proposed sale, amended | Aug 27, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 27, 2025 | Other filings | SEC |
| 8-K · Current report | Aug 11, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 11, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2025 | Current report | SEC |
| ARS · Annual report to shareholders | Jul 31, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jul 31, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jul 31, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jul 18, 2025 | Management or board change | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | Apr 17, 2025 | Current report | SEC |
| 424B5 · Prospectus | Apr 17, 2025 | Offer document | SEC |
| 4/A · Change in ownership, amended | Mar 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 13, 2025 | Results | SEC |
| 10-K · Annual report | Mar 13, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 4, 2025 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 7, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 6, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 3, 2025 | Offer document | SEC |
| SCHEDULE 13D · Big-stake notice | Jan 29, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 15, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Dec 23, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Dec 20, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Nov 25, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Nov 25, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 21, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 20, 2024 | Other filings | SEC |
| S-3 · Registration statement | Nov 14, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| D | Nov 14, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 8-K · Current report | Nov 4, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Nov 4, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 24, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Oct 4, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Sep 25, 2024 | Current report | SEC |
| 8-K · Current report | Sep 5, 2024 | Current report | SEC |
| 8-K · Current report | Aug 20, 2024 | Current report | SEC |
| 8-K · Current report | Aug 16, 2024 | Current report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2024 | Current report | SEC |
| 8-K · Current report | Jul 31, 2024 | Management or board change | SEC |
| DEFA14A · Additional proxy material | Jun 12, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Jun 11, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Jun 11, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | May 29, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2024 | Current report | SEC |
| 4 · Change in ownership | Apr 10, 2024 | Insider trade | SEC |
| 8-K · Current report | Apr 9, 2024 | Current report | SEC |
| 4 · Change in ownership | Apr 3, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 3, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Apr 3, 2024 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Apr 1, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Mar 21, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 18, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 15, 2024 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 12, 2024 | Offer document | SEC |
| S-3 · Registration statement | Mar 12, 2024 | Offer document | SEC |
| 8-K · Current report | Mar 11, 2024 | Material contract | SEC |
| 8-K · Current report | Mar 11, 2024 | Results | SEC |
| 10-K · Annual report | Mar 8, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2024 | Current report | SEC |
| 8-K/A · Current report, amended | Feb 15, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 12, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 12, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jan 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 19, 2024 | Insider trade | SEC |
This page holds 200 of 279 filings. Open Filings
Cap table
Built by 6ix from Cadrenal Therapeutics, Inc.’s releases · as of Nov 16, 2026
- Common shares
- 4,122,081
- Fully diluted
- 4,122,081
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 4,122,081 | Nov 16, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 16, 2026 | 4,122,081 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Matthew K Szot Other companies: INVO Fertility, Inc. (Director · Since at least Sep 13, 2020); SenesTech, Inc. (Director · Since at least Dec 18, 2017); Beeline Holdings, Inc. (Director · Jun 18, 2018 – Jun 30, 2019 · Past); S&W Seed Company (EVP Finance & Admin and CFO · Oct 1, 2017 – Oct 5, 2021 · Past) | Chief Financial Officer · Since at least Jan 19, 2023 |
| Glynn Wilson Other companies: Caring Brands, Inc. (Chief Executive Officer, Director · Since at least Oct 30, 2025); Bonk, Inc. (Former CSO, Chairman, Director · Oct 30, 2020 – Mar 1, 2024 · Past); Marker Therapeutics, Inc. (Director · Jun 8, 2007 – Oct 9, 2018 · Past) | Board Member · Since at least Jan 19, 2023 |
| Steven Zelenkofske Other companies: Achillion Pharmaceuticals Inc (EVP, Chief Medical Officer · Aug 20, 2018 – Jan 28, 2020 · Past); uniQure N.V. (Chief Medical Officer · Jun 5, 2017 – Jun 6, 2018 · Past); Tobira Therapeutics Inc (SVP & Chief Medical Officer · Aug 21, 2013 – Jan 1, 2014 · Past) | Director · Jan 19, 2023 – Jan 23, 2025 · Past |
| James J Ferguson III Other companies: Mineralys Therapeutics, Inc. (Chief Medical Officer · Since at least Aug 10, 2026); Matinas BioPharma Holdings, Inc. (Chief Medical Officer · Feb 25, 2019 – Dec 15, 2023 · Past) | Chief Medical Officer · Feb 5, 2025 – Feb 5, 2025 · Past |
| John R. Murphy Other companies: O'Reilly Automotive, Inc. (Director · Since at least May 13, 2022); Summit Materials Inc (Director · Feb 22, 2023 – Sep 29, 2023 · Past) | Board Member · Since at least Jan 19, 2023 |
| Lee Golden Other companies: PTC Therapeutics, Inc. (EVP & CHIEF MEDICAL OFFICER · Since at least Jun 6, 2023); MetaVia Inc. (Chief Medical Officer · Oct 5, 2016 – Jan 28, 2018 · Past) | Board Member · Since at least Nov 24, 2025 |
| Robert Lisicki Other companies: Zura Bio Limited (Chief Executive Officer, Director · Jan 8, 2024 – Feb 27, 2025 · Past); Arena Pharmaceuticals Inc (EVP, Chief Commercial Officer · Aug 4, 2020 – Mar 11, 2022 · Past) | Director · Jul 23, 2023 – Jan 23, 2025 · Past |
| Quang Pham Other companies: Monarch Staffing, Inc. (Chief Operating Officer, Pres. · Jul 1, 2007 – Jul 1, 2007 · Past) | Chairman & Chief Executive Officer · Since at least Jan 19, 2023 |
| James J. Ferguson | Chief Medical Officer · May 8, 2025 – Nov 5, 2026 · Past |
| Jeff Cole | Chief Operating Officer · Since at least Mar 13, 2025 |
All 12 people
| Person | Seat |
|---|---|
| Jeffrey Scott Cole | Chief Operating Officer · Feb 7, 2024 – Jan 23, 2025 · Past |
| John P. Sharp | Interim Chief Financial Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Cadrenal Therapeutics, Inc.